
Steve E Kalloger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7818929/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?. Clinical Cancer Research, 2021, 27, 246-254.	3.2	16
2	Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Clinical Cancer Research, 2021, 27, 150-157.	3.2	24
3	Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 719-726.	1.4	3
4	Stroma vs epitheliumâ€enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma. International Journal of Cancer, 2021, 148, 481-491.	2.3	7
5	Modelling hereditary diffuse gastric cancer initiation using transgenic mouseâ€derived gastric organoids and singleâ€cell sequencing. Journal of Pathology, 2021, 254, 254-264.	2.1	11
6	Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma. Cancer Medicine, 2021, 10, 1155-1165.	1.3	9
7	Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue. Biomarker Insights, 2021, 16, 117727192110498.	1.0	1
8	Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms. Cell Reports, 2021, 37, 109817.	2.9	14
9	Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. Clinical Cancer Research, 2020, 26, 135-146.	3.2	121
10	Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication. Health Expectations, 2020, 23, 884-892.	1.1	15
11	Loss of switch/sucrose nonâ€fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas. Histopathology, 2020, 77, 46-54.	1.6	39
12	Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types. Molecular Cancer Therapeutics, 2020, 19, 1889-1897.	1.9	10
13	Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening. Cancer Medicine, 2020, 9, 4004-4013.	1.3	25
14	Mitochondrial DNA somatic mutation burden and heteroplasmy are associated with chronological age, smoking, and HIV infection. Aging Cell, 2019, 18, e13018.	3.0	27
15	Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. Gastroenterology, 2019, 157, 823-837.	0.6	153
16	Dynamics of leukocyte telomere length in pregnant women living with HIV, and HIV-negative pregnant women: A longitudinal observational study. PLoS ONE, 2019, 14, e0212273.	1.1	7
17	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002329.	0.5	30
18	Temporal Dynamics of Genomic Alterations in a BRCA1 Germline–Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan. JCO Precision Oncology, 2018, 2, 1-8.	1.5	1

#	Article	IF	CITATIONS
19	Increased Cancer Risk in Younger Patients with Thyroid Nodules Diagnosed as Atypia of Undetermined Significance. Cureus, 2018, 10, e2348.	0.2	4
20	siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 569-590.	2.3	17
21	A predictive analysis of the SP120 and 10D7C2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. Journal of Pathology: Clinical Research, 2017, 3, 179-190.	1.3	12
22	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer, 2017, 17, 618.	1.1	42
23	Classification of Extraovarian Implants in Patients With Ovarian Serous Borderline Tumors (Tumors) Tj ETQq1 1 2016, 40, 1155-1164.	0.784314	rgBT /Overloc 30
24	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nature Genetics, 2016, 48, 758-767.	9.4	287
25	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non–small Cell Lung Cancer. Journal of Histochemistry and Cytochemistry, 2016, 64, 587-600.	1.3	30
26	Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups. Journal of Clinical Pathology, 2016, 69, 431-439.	1.0	19
27	Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction. PLoS ONE, 2016, 11, e0153844.	1.1	17
28	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids. Nature Medicine, 2015, 21, 1364-1371.	15.2	591
29	Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Modern Pathology, 2015, 28, 1383-1389.	2.9	51
30	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget, 2015, 6, 39088-39097.	0.8	67
31	HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. Oncotarget, 2015, 6, 33705-33719.	0.8	28
32	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Modern Pathology, 2014, 27, 255-261.	2.9	110
33	HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1495-1502.	1.2	31
34	Current Morphologic Criteria Perform Poorly in Identifying Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Uterine Leiomyomas. International Journal of Gynecological Pathology, 2014, 33, 560-567.	0.9	25
35	ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Human Pathology, 2014, 45, 1258-1268.	1.1	34
36	Expression of Matrix Metalloproteinase-1 in Alveolar Macrophages, Type II Pneumocytes, and Airways in Smokers: Relationship to Lung Function and Emphysema. Lung, 2014, 192, 467-472.	1.4	5

#	Article	IF	CITATIONS
37	Determinants of Quality of Life in Ovarian Cancer Survivors: A Pilot Study. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 708-715.	0.3	30
38	Reproducibility of histological cell type in high-grade endometrial carcinoma. Modern Pathology, 2013, 26, 1594-1604.	2.9	167
39	The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Modern Pathology, 2013, 26, 1255-1263.	2.9	52
40	Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository. Biopreservation and Biobanking, 2013, 11, 83-93.	0.5	35
41	Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecologic Oncology, 2013, 128, 371-376.	0.6	63
42	Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle, 2013, 12, 1433-1449.	1.3	78
43	Stage II to IV Low-grade Serous Carcinoma of the Ovary Is Associated With a Poor Prognosis. International Journal of Gynecological Pathology, 2013, 32, 529-535.	0.9	34
44	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1677-1686.	1.1	70
45	Accelerating typeâ€specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (<scp>COSP</scp>) is a reliable highâ€throughput tool for case review. Histopathology, 2013, 63, 704-712.	1.6	5
46	Type-Specific Cell Line Models for Type-Specific Ovarian Cancer Research. PLoS ONE, 2013, 8, e72162.	1.1	200
47	Markers of T Cell Infiltration and Function Associate with Favorable Outcome in Vascularized High-Grade Serous Ovarian Carcinoma. PLoS ONE, 2013, 8, e82406.	1.1	22
48	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Modern Pathology, 2012, 25, 740-750.	2.9	151
49	Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma. International Journal of Gynecological Pathology, 2012, 31, 397-404.	0.9	25
50	Transitional Cell Carcinoma of the Ovary is Related to High-grade Serous Carcinoma and is Distinct From Malignant Brenner Tumor. International Journal of Gynecological Pathology, 2012, 31, 499-506.	0.9	65
51	Recurrent Somatic <i>DICER1</i> Mutations in Nonepithelial Ovarian Cancers. New England Journal of Medicine, 2012, 366, 234-242.	13.9	401
52	Use of Mismatch Repair Immunohistochemistry and Microsatellite Instability Testing. American Journal of Surgical Pathology, 2012, 36, 560-569.	2.1	23
53	HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. Histopathology, 2012, 60, 547-553.	1.6	25
54	Nucleic acid quantity and quality from paraffin blocks: Defining optimal fixation, processing and DNA/RNA extraction techniques. Experimental and Molecular Pathology, 2012, 92, 33-43.	0.9	100

#	Article	IF	CITATIONS
55	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutationâ€positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer, 2012, 118, 681-688.	2.0	71
56	The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. Clinical and Experimental Metastasis, 2012, 29, 239-252.	1.7	50
57	Histologic Artifacts in Abdominal, Vaginal, Laparoscopic, and Robotic Hysterectomy Specimens. American Journal of Surgical Pathology, 2011, 35, 115-126.	2.1	74
58	Biomarker Expression in Pelvic High-grade Serous Carcinoma. International Journal of Gynecological Pathology, 2011, 30, 366-371.	0.9	34
59	FOXL2 Is a Sensitive and Specific Marker for Sex Cord-Stromal Tumors of the Ovary. American Journal of Surgical Pathology, 2011, 35, 484-494.	2.1	183
60	In-Depth Proteomics of Ovarian Cancer Ascites: Combining Shotgun Proteomics and Selected Reaction Monitoring Mass Spectrometry. Journal of Proteome Research, 2011, 10, 2286-2299.	1.8	72
61	Calculator for ovarian carcinoma subtype prediction. Modern Pathology, 2011, 24, 512-521.	2.9	95
62	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 2011, 17, 2538-2548.	3.2	217
63	Claudin 4 Is Differentially Expressed between Ovarian Cancer Subtypes and Plays a Role in Spheroid Formation. International Journal of Molecular Sciences, 2011, 12, 1334-1358.	1.8	33
64	Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible. American Journal of Surgical Pathology, 2010, 34, 984-993.	2.1	143
65	Primary Ovarian Mucinous Carcinoma of Intestinal Type: Significance of Pattern of Invasion and Immunohistochemical Expression Profile in a Series of 31 Cases. International Journal of Gynecological Pathology, 2010, 29, 99-107.	0.9	90
66	Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas. International Journal of Gynecological Pathology, 2010, 29, 203-211.	0.9	332
67	High-Grade Endometrial Carcinoma: Serous and Grade 3 Endometrioid Carcinomas Have Different Immunophenotypes and Outcomes. International Journal of Gynecological Pathology, 2010, 29, 343-350.	0.9	146
68	Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecologic Oncology, 2010, 116, 50-56.	0.6	129
69	Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-12 Pathway Signaling Indicates Response to Primary Chemotherapy. Clinical Cancer Research, 2010, 16, 2852-2860.	3.2	58
70	Nectin 4 Overexpression in Ovarian Cancer Tissues and Serum. American Journal of Clinical Pathology, 2010, 134, 835-845.	0.4	152
71	<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas. New England Journal of Medicine, 2010, 363, 1532-1543.	13.9	1,460
72	S100A1 Expression in Ovarian and Endometrial Endometrioid Carcinomas Is a Prognostic Indicator of Relapse-Free Survival. American Journal of Clinical Pathology, 2009, 132, 846-856.	0.4	42

#	Article	IF	CITATIONS
73	Regulation of HSulf-1 Expression by Variant Hepatic Nuclear Factor 1 in Ovarian Cancer. Cancer Research, 2009, 69, 4843-4850.	0.4	40
74	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology, 2009, 22, 393-402.	2.9	241
75	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathology, 2009, 22, 469-475.	2.9	125
76	Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary. New England Journal of Medicine, 2009, 360, 2719-2729.	13.9	706
77	A Limited Panel of Immunomarkers Can Reliably Distinguish Between Clear Cell and High-grade Serous Carcinoma of the Ovary. American Journal of Surgical Pathology, 2009, 33, 14-21.	2.1	211
78	Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes and Cancer, 2008, 47, 481-489.	1.5	116
79	The prognostic significance of elongation factor eEF1A2 in ovarian cancer. Gynecologic Oncology, 2008, 108, 561-568.	0.6	47
80	Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas. Neoplasia, 2008, 10, 1021-1027.	2.3	158
81	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Human Pathology, 2008, 39, 1239-1251.	1.1	231
82	Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies. PLoS Medicine, 2008, 5, e232.	3.9	675
83	Amplification of <i>PVT1</i> Contributes to the Pathophysiology of Ovarian and Breast Cancer. Clinical Cancer Research, 2007, 13, 5745-5755.	3.2	345
84	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Medicine, 2007, 5, 33.	2.3	52
85	Tomographic Comparison of Ventilation Techniques for CT-Guided Thoracoscopic Staple Excision of Subcentimeter Lung Nodules. Journal of Investigative Surgery, 2006, 19, 185-191.	0.6	1
86	CT-Directed Microcoil Localization of Small Peripheral Lung Nodules: A Feasibility Study in Pigs. Journal of Investigative Surgery, 2005, 18, 265-272.	0.6	16
87	Detection of Lung Perfusion Abnormalities Using Computed Tomography in a Porcine Model of Pulmonary Embolism. Journal of Thoracic Imaging, 2003, 18, 14-20.	0.8	43